ArticleJAMA network open2025
Epstein-Barr Virus Seropositivity, Immune Dysregulation, and Mortality in Pediatric Sepsis.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The epigenetic-immune-microbiome axis in early life: reprogramming the origins and endotypes of pediatric asthma.Frontiers in immunology · 2026Review
- The Interleukin Network in Sepsis: From Cytokine Storm to Clinical Applications.Diagnostics (Basel, Switzerland) · 2025Review
- Causal Discovery in Sepsis-A (Random) Walk in the Park?JAMA network open · 2025Article
- Impact of Epstein-Barr virus infection on clinical outcomes and immune profiles in patients with severe fever with thrombocytopenia syndrome.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Epstein-Barr virus (EBV) seropositivity is associated with chronic immune dysregulation conditions, including multiple sclerosis, systemic lupus erythematosus, post-COVID-19 condition, and multiple cancers. Sepsis is an acute immune dysregulation condition attributed to 1 of 5 global deaths. Objective: To assess causal associations among EBV seropositivity, immune dysregulation, and mortality in children with sepsis. Design, Setting, and Participants: This cohort study analyzed 320 children with sepsis in the 9-center Eunice Kennedy Shriver National Institutes of Child Health and Development Collaborative Pediatric Critical Care Research Network Phenotyping Pediatric Sepsis-Induced Multiple Organ Failure (PHENOMS) study who had not previously received intravenous immune globulin. Blood samples and clinical data were collected from January 1, 2015, to December 31, 2018, and assayed from January 1, 2019, to December 31, 2022. Causal algorithms were modeled in directed acyclic graphs and subsequent sensitivity and mediation analyses applied with further confirmation by structural equation modeling. Data analysis was performed from May 2022 to January 2025. Intervention: Blood sample collected at 24 to 48 hours of sepsis. Main Outcomes and Measures: Circulating biomarkers of inflammation (C-reactive protein, ferritin, and 32 cytokines), immune depression (ex vivo tumor necrosis factor response to endotoxin < 200 pg/mL), thrombotic microangiopathy (ADAMTS13 activity <57%), and EBV seropositivity (viral capsid IgG) were measured. Causal inference analysis identified causal associations between EBV seropositivity, immune dysregulation biomarkers, macrophage activation syndrome, and death. Results: Of the 320 children (median [IQR] age, 6 [1-12] years; 172 [53.8%] male), 150 (46.9%) were previously healthy, and 72 (22.5%) had immunocompromise at admission. A total of 172 (53.8%) had causal associations with death directly and through the mediators hyperferritinemia and macrophage activation syndrome (MAS) and also had direct causal associations with increased C-reactive protein, ferritin, and interleukin 18 binding protein, which in turn had direct causal associations with decreased ADAMTS 13 activity and decreased whole blood ex vivo tumor necrosis factor response to endotoxin. Mediation analysis found that EBV seropositivity was associated with mortality (estimate [SE], 1.86 [0.55]; P < .001). With both EBV seropositivity and ferritin included in the model, the effect of EBV seropositivity on death remained (estimate [SE], 1.52 [0.57]; P = .007), as did the ferritin effect (estimate [SE], 0.50 [0.15]; P = .001). EBV seropositivity remained significantly associated with death even after adjustment for MAS (estimate [SE], 1.78 [0.56]; P = .001). Conclusions and Relevance: In this cohort study of pediatric sepsis, EBV seropositivity was associated with immune dysregulation and mortality. Further study is warranted to address the possibility that latent EBV infection immune reprogramming poses an important public health problem that contributes to not only chronic disorders of immune dysregulation but also acute disorders of immune dysregulation, such as sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.